JP Morgan Chase
SMMT icon

JP Morgan Chase’s Summit Therapeutics SMMT Stock Holding History

JP Morgan Chase’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100
Closed -$1.93K – 7594
2025
Q1 		$1.93K Buy
+100
New +$2.01K ﹤0.01% 6548

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

JP Morgan Chase's SMMT Position: Q2 2026 in Review

JP Morgan Chase increased its Summit Therapeutics (SMMT) stake by 5.6% in Q2 2026, buying an estimated $64.1K and bringing the position to 68,169 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #4624.

JP Morgan Chase first reported a position in SMMT in Q4 2017 and has held it in 27 quarters since. The position peaked at $11.1M in Q1 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • JP Morgan Chase held 68,169 shares of Summit Therapeutics worth $1.07M as of Q2 2026.
  • JP Morgan Chase bought 3,615 Summit Therapeutics shares in Q2 2026, an estimated $64.1K.
  • Summit Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4624 holding.
  • JP Morgan Chase first reported a position in Summit Therapeutics in Q4 2017 and has held it in 27 quarters since.
  • JP Morgan Chase's Summit Therapeutics position peaked at $11.1M in Q1 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.